A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Tóm tắt tin
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Theo dõi tin mới từ các nhà xuất bản đáng tin cậy cùng phần tóm tắt ngắn. Mở liên kết nguồn gốc để xem chi tiết.